{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:17:34Z","timestamp":1788445054880,"version":"build-2803163510"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neurofilament light chain (NfL) has emerged as a promising blood-based biomarker for neuroaxonal damage across neurological disorders. Clinical utility has been correlated with disease activity, treatment response, and prognosis. However, routine clinical laboratory implementation requires comprehensive analytical validation to ensure reliability and accuracy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A fully automated Access NfL research use only (RUO) immunoassay was evaluated on the DxI 9000 Immunoassay Analyzer from Beckman Coulter. Analytical validation in plasma assessed precision, analytical sensitivity, linearity, analytical specificity (interference), calibrator and sample stability, and method comparison to the Quanterix Simoa NfL assay. Clinical validity included comparisons of Alzheimer disease (Ad, N = 20) in plasma and multiple sclerosis (MS, N = 16) in serum, vs healthy controls (N = 20 and N = 23, respectively). Plasma\u2212serum equivalence was validated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The NfL assay met analytical criteria, with precision demonstrating coefficients of variation &amp;lt;3% across runs, a lower limit of quantification of 3.10 pg\/mL, linearity with &amp;lt;12% deviation, and &amp;lt;10% interference. Plasma NfL samples remained stable for 18 h at room temperature (&amp;lt;7% difference) and refrigerated (&amp;lt;5%), and through 5 freeze\u2212thaw cycles (&amp;lt;8%). Method comparison yielded high correlation (R2 = 0.981) with positive systematic proportional bias (Passing\u2013Bablok slope = 3.02). Ad patients showed significantly elevated NfL levels (median 49.3 pg\/mL, IQR: 28.9\u201367.8) vs controls (median 29.1 pg\/mL, IQR: 22.6\u201333.8; P = 0.02). MS patients similarly demonstrated higher NfL (median 27.7 pg\/mL, IQR: 22.5\u201350.6) vs controls (median 19.2 pg\/mL, IQR: 15.1\u201325.6; P = 0.003).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The high-throughput Access NfL assay demonstrated analytical and clinical validity, supporting implementation in research and clinical laboratories.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jalm\/jfag052","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:45:11Z","timestamp":1775821511000},"page":"1161-1173","source":"Crossref","is-referenced-by-count":0,"title":["Analytical and Clinical Validity of a High-Throughput, Fully Automated Immunoassay for Plasma Neurofilament Light Chain"],"prefix":"10.1093","volume":"11","author":[{"given":"Dusten","family":"Unruh","sequence":"first","affiliation":[{"name":"Beckman Coulter Diagnostics , Chaska, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Todtleben","sequence":"additional","affiliation":[{"name":"Beckman Coulter Diagnostics , Chaska, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Johnson","sequence":"additional","affiliation":[{"name":"Beckman Coulter Diagnostics , Chaska, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Schlichtmann","sequence":"additional","affiliation":[{"name":"Beckman Coulter Diagnostics , Chaska, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miklos","family":"Szabo","sequence":"additional","affiliation":[{"name":"Beckman Coulter Diagnostics , Chaska, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Holland","sequence":"additional","affiliation":[{"name":"Beckman Coulter Diagnostics , Chaska, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Carlson","sequence":"additional","affiliation":[{"name":"Beckman Coulter Diagnostics , Chaska, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah","family":"Hinson","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Johns Hopkins University School of Medicine , Baltimore, MD ,","place":["United States"]},{"name":"Danaher Diagnostics , Washington, DC ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7143-7635","authenticated-orcid":false,"given":"Scott","family":"Levin","sequence":"additional","affiliation":[{"name":"Danaher Diagnostics , Washington, DC ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"2026090309522322700_jfag052-B1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","article-title":"Neurofilaments as biomarkers in neurological disorders\u2014towards clinical application","volume":"20","author":"Khalil","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"2026090309522322700_jfag052-B2","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology"},{"key":"2026090309522322700_jfag052-B3","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026090309522322700_jfag052-B4","doi-asserted-by":"crossref","first-page":"e0274565","DOI":"10.1371\/journal.pone.0274565","article-title":"Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: a systematic review and meta-analysis","volume":"17","author":"Ning","year":"2022","journal-title":"PLoS One"},{"key":"2026090309522322700_jfag052-B5","doi-asserted-by":"crossref","first-page":"104970","DOI":"10.1016\/j.ebiom.2024.104970","article-title":"Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","volume":"101","author":"Freedman","year":"2024","journal-title":"EBioMedicine"},{"key":"2026090309522322700_jfag052-B6","doi-asserted-by":"crossref","first-page":"935382","DOI":"10.3389\/fneur.2022.935382","article-title":"Development of a highly sensitive neurofilament light chain assay on an automated immunoassay platform","volume":"13","author":"Lee","year":"2022","journal-title":"Front Neurol"},{"key":"2026090309522322700_jfag052-B7","doi-asserted-by":"crossref","first-page":"119817","DOI":"10.1016\/j.cca.2024.119817","article-title":"Head-to-head comparison of four plasma neurofilament light chain (NfL) immunoassays","volume":"561","author":"Ashrafzadeh-Kian","year":"2024","journal-title":"Clin Chim Acta"},{"key":"2026090309522322700_jfag052-B8","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann Neurol"},{"key":"2026090309522322700_jfag052-B9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cca.2022.08.017","article-title":"Plasma neurofilament light chain (NfL) reference interval determination in an age-stratified cognitively unimpaired cohort","volume":"535","author":"Bornhorst","year":"2022","journal-title":"Clin Chim Acta"},{"key":"2026090309522322700_jfag052-B10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol"},{"key":"2026090309522322700_jfag052-B11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/acn3.50972","article-title":"Confounding effect of blood volume and body mass index on blood neurofilament light chain levels","volume":"7","author":"Manouchehrinia","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"2026090309522322700_jfag052-B12","author":"Clinical and Laboratory Standards Institute (CLSI)"},{"key":"2026090309522322700_jfag052-B13","doi-asserted-by":"crossref","first-page":"fcae247","DOI":"10.1093\/braincomms\/fcae247","article-title":"Multi-peptide characterization of plasma neurofilament light chain in preclinical and mild Alzheimer\u2019s disease","volume":"6","author":"Coulton","year":"2024","journal-title":"Brain Commun"},{"key":"2026090309522322700_jfag052-B14","doi-asserted-by":"crossref","first-page":"fcac045","DOI":"10.1093\/braincomms\/fcac045","article-title":"A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer\u2019s disease","volume":"4","author":"Budelier","year":"2022","journal-title":"Brain Commun"},{"key":"2026090309522322700_jfag052-B15","doi-asserted-by":"crossref","first-page":"fcae132","DOI":"10.1093\/braincomms\/fcae132","article-title":"CSF neurofilament light chain profiling and quantitation in neurological diseases","volume":"6","author":"Leckey","year":"2024","journal-title":"Brain Commun"},{"key":"2026090309522322700_jfag052-B16"},{"key":"2026090309522322700_jfag052-B17"},{"key":"2026090309522322700_jfag052-B18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"2026090309522322700_jfag052-B19","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"2026090309522322700_jfag052-B20","author":"CLSI"},{"key":"2026090309522322700_jfag052-B21","author":"CLSI"},{"key":"2026090309522322700_jfag052-B22","author":"CLSI"},{"key":"2026090309522322700_jfag052-B23","author":"CLSI"},{"key":"2026090309522322700_jfag052-B24","author":"CLSI"},{"key":"2026090309522322700_jfag052-B25","author":"CLSI"},{"key":"2026090309522322700_jfag052-B26","doi-asserted-by":"crossref","first-page":"7494","DOI":"10.1007\/s00415-024-12701-w","article-title":"In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting","volume":"271","author":"Malucchi","year":"2024","journal-title":"J Neurol"},{"key":"2026090309522322700_jfag052-B27","doi-asserted-by":"crossref","first-page":"120447","DOI":"10.1016\/j.cca.2025.120447","article-title":"Validation and generation of age-specific reference intervals for a new blood neurofilament light chain assay","volume":"577","author":"Booth","year":"2025","journal-title":"Clin Chim Acta"},{"key":"2026090309522322700_jfag052-B28","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1515\/cclm-2023-0518","article-title":"Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury","volume":"62","author":"Wilson","year":"2024","journal-title":"Clin Chem Lab Med"},{"key":"2026090309522322700_jfag052-B29","doi-asserted-by":"crossref","first-page":"10381","DOI":"10.1038\/s41598-020-67504-6","article-title":"Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis","volume":"10","author":"Thebault","year":"2020","journal-title":"Sci Rep"},{"key":"2026090309522322700_jfag052-B30","doi-asserted-by":"crossref","first-page":"894119","DOI":"10.3389\/fneur.2022.894119","article-title":"A method to combine neurofilament light measurements from blood Serum and plasma in clinical and population-based studies","volume":"13","author":"R\u00fcbsamen","year":"2022","journal-title":"Front Neurol"},{"key":"2026090309522322700_jfag052-B31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.21037\/jlpm-24-33","article-title":"Determination of pediatric and adult reference intervals for neurofilament light chain (NfL) in blood and a comparison to other recent studies","volume":"9","author":"Figdore","year":"2024","journal-title":"J Lab Precis Med"},{"key":"2026090309522322700_jfag052-B32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.31083\/j.jin2204085","article-title":"Neurofilament light chain as a potential biomarker in plasma for Alzheimer\u2019s disease and mild cognitive impairment: a systematic review and a meta-analysis","volume":"22","author":"Fan","year":"2023","journal-title":"J Integr Neurosci"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/11\/5\/1161\/68370454\/jfag052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/11\/5\/1161\/68370454\/jfag052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:52:34Z","timestamp":1788443554000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/11\/5\/1161\/8690902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,22]]},"published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfag052","relation":{},"ISSN":["2475-7241"],"issn-type":[{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,5,22]]}}}